Chinese brain interface startup Gestala raises $21M just two months after launch

Here’s a rewritten version of the tech news article with a detailed, informative, and viral tone, followed by a list of tags and viral phrases:

Breaking: China’s Brain-Computer Interface Race Heats Up as Gestala Rockets to $21.6M Valuation in Record Time

In a stunning display of China’s burgeoning deep-tech prowess, Phoenix Peng’s ultrasound-based brain-computer interface (BCI) startup, Gestala, has secured a whopping $21.6 million (CN¥150 million) in funding just two months after its launch. This monumental early-stage investment, co-led by Guosheng Capital and Dalton Venture, catapults Gestala to a valuation between $100 million and $200 million, marking it as the largest seed funding round in China’s BCI industry to date.

The race for brain-computer interface dominance is intensifying, with Elon Musk’s Neuralink and OpenAI-backed Merge Labs leading the charge in the United States. However, Peng’s dual-pronged approach through NeuroXess (developing implantable BCIs) and Gestala (focusing on non-invasive ultrasound BCIs) signals China’s intent to be a major player in this revolutionary field.

Gestala’s ultrasound technology offers a compelling alternative to invasive brain surgery, a significant barrier to BCI adoption. By leveraging phased-array ultrasound, the system can monitor and stimulate neural activity across a larger portion of the brain, including deep neural circuits, without the need for surgical intervention. This non-invasive approach could be a game-changer, opening up BCI technology to a much wider audience.

The global BCI industry is experiencing an unprecedented investment surge, particularly in ultrasound technology. While Gestala is the first ultrasound BCI company in China, several U.S.-based startups, including the well-funded Merge Labs, are also exploring this promising avenue. Peng believes ultrasound represents the next generation of BCI technology, offering the potential for broader, whole-brain access and novel ways to interact with neural activity.

Despite the current geopolitical tensions, Peng remains optimistic about potential collaboration between the U.S. and China in deep-tech research. He highlights the complementary strengths of both nations: China’s large-scale clinical research capacity and efficient supply chains, coupled with the U.S.’s world-class scientific talent. Joint efforts could focus on building large clinical datasets to support global neuroscience research, accelerating progress in this critical field.

Gestala is targeting several key applications for its technology. Chronic pain management is the startup’s lead program, addressing a significant unmet need in both the U.S. and China. Academic studies suggest that ultrasound stimulation can significantly reduce pain levels, offering a non-pharmacological alternative for millions of sufferers. The company is also exploring applications in mental health conditions such as depression, PTSD, autism, and OCD, as well as stroke rehabilitation. Longer-term targets include Alzheimer’s disease, essential tremor, and Parkinson’s disease.

Gestala believes its competitive advantage lies in speed and scale. By leveraging China’s integrated manufacturing ecosystem, the startup aims to move from development to production faster than many international competitors. Furthermore, Gestala is working with major Chinese hospitals to accelerate clinical trials at a fraction of the cost of comparable studies in the U.S. or Europe. The company is also building an “Ultrasound Brain Bank,” a large clinical dataset designed to train AI models to decode brain signals and support future neurological diagnostics.

With plans to expand its team from 15 to 35 employees by year-end and build a manufacturing facility in China, Gestala is poised for rapid growth. The company aims to complete its first-generation prototype by the end of the year, bringing this revolutionary technology one step closer to reality. As the BCI race heats up, all eyes will be on Gestala to see if it can deliver on its ambitious promises and usher in a new era of non-invasive brain-computer interfaces.

Tags: Brain-Computer Interface, BCI, Ultrasound Technology, Neuralink, OpenAI, Merge Labs, NeuroXess, Gestala, Phoenix Peng, China Tech, Deep Tech, Medical Technology, Chronic Pain, Mental Health, Stroke Rehabilitation, Alzheimer’s Disease, Parkinson’s Disease, Neuroscience, AI, Clinical Trials, Manufacturing, Investment, Valuation, Silicon Valley, Beijing, Innovation

Viral Phrases:

• “Revolutionizing brain-computer interfaces with ultrasound”
• “China’s BCI startup rockets to $21.6M valuation in record time”
• “Non-invasive BCI technology: The future of brain-computer interaction?”
• “Gestala: Challenging Neuralink with ultrasound-based BCI”
• “The race for brain-computer interface dominance heats up”
• “Ultrasound BCI: Monitoring and stimulating the brain without surgery”
• “China’s deep-tech prowess on display with Gestala’s massive funding round”
• “Can Gestala deliver on its ambitious promises and disrupt the BCI market?”
• “The potential of ultrasound BCI: From chronic pain to Alzheimer’s disease”
• “Gestala’s ‘Ultrasound Brain Bank’: Training AI to decode brain signals”
• “Speed and scale: Gestala’s competitive advantage in the BCI race”
• “Will the U.S. and China collaborate on deep-tech research despite tensions?”
• “Gestala’s first-generation prototype: A glimpse into the future of BCI”
• “The BCI industry is experiencing an unprecedented investment surge”
• “Ultrasound technology: The next generation of brain-computer interface?”

,